- Home
- CAPR vs MRVI Comparison
CAPR vs MRVI Comparison
Compare CAPR & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- MRVI
- Stock Information
- Founded
- CAPR 2005
- MRVI 2020
- Country
- CAPR United States
- MRVI United States
- Employees
- CAPR N/A
- MRVI N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- MRVI Health Care
- Exchange
- CAPR Nasdaq
- MRVI Nasdaq
- Market Cap
- CAPR 867.6M
- MRVI 809.2M
- IPO Year
- CAPR N/A
- MRVI 2020
- Fundamental
- Price
- CAPR $13.07
- MRVI $5.37
- Analyst Decision
- CAPR Strong Buy
- MRVI Buy
- Analyst Count
- CAPR 7
- MRVI 10
- Target Price
- CAPR $39.29
- MRVI $10.28
- AVG Volume (30 Days)
- CAPR 1.8M
- MRVI 1.7M
- Earning Date
- CAPR 11-13-2024
- MRVI 02-20-2025
- Dividend Yield
- CAPR N/A
- MRVI N/A
- EPS Growth
- CAPR N/A
- MRVI N/A
- EPS
- CAPR N/A
- MRVI N/A
- Revenue
- CAPR $23,228,045.00
- MRVI $276,920,000.00
- Revenue This Year
- CAPR N/A
- MRVI N/A
- Revenue Next Year
- CAPR $74.85
- MRVI $3.41
- P/E Ratio
- CAPR N/A
- MRVI N/A
- Revenue Growth
- CAPR 65.33
- MRVI N/A
- 52 Week Low
- CAPR $3.52
- MRVI $4.28
- 52 Week High
- CAPR $23.40
- MRVI $11.56
- Technical
- Relative Strength Index (RSI)
- CAPR 37.42
- MRVI 43.61
- Support Level
- CAPR $12.25
- MRVI $5.30
- Resistance Level
- CAPR $20.75
- MRVI $6.01
- Average True Range (ATR)
- CAPR 1.62
- MRVI 0.35
- MACD
- CAPR -0.24
- MRVI 0.06
- Stochastic Oscillator
- CAPR 9.65
- MRVI 31.37
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.